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Background: Individual trials are often underpowered to show differences in rare
adverse clinical events such as very late stent thrombosis (VLST; after one-year,
definite + probable ST). The RESOLUTE clinical program comprises 5 trials
prospectively designed with similar definitions, and adjudication procedures, that
allows pooled analysis of clinical endpoints.
Methods: Over 5,000 patients treated with the Resolute zotarolimus-eluting stent (R-
ZES) were pooled from the RESOLUTE All Comers randomized trial, comparing
R-ZES (N = 1140; 2 yr follow-up) with the XIENCE V everolimus-eluting stent (EES,
N=1152) and 4 single-arm studies: the RESOLUTE first-in-human (N = 139; R-FIM,
4 yr follow-up); the open label RESOLUTE International (N=2349; R-Int, 1 yr follow-
up); RESOLUTE Japan (N=100; 1 yr follow-up); and RESOLUTE US (N=1402; 1 yr
follow-up). Pooled safety endpoints (cardiac death, myocardial infarction [MI], and
VLST) for R-ZES patients were compared with EES patients from Resolute All
Comers. Pooled outcomes of single-vessel treated R-ZES patients (N = 2466) were
compared with BMS-treated patients (N = 596) from the ENDEAVOR II randomized
trial. RESOLUTE trials recommended six months dual antiplatelet therapy (DAPT);
ENDEAVOR II patients received 12 weeks of DAPT. Propensity scores were used to
adjust for differences in patient characteristics.
Results: At two years, the cumulative frequency of ST was 1.0% for R-ZES and EES
(adjusted hazard ratio 1.335; p=0.424) and VLST was 0.2% for R-ZES and 0.3% for
EES (adjusted hazard ratio 0.908; p=0.906). The cumulative ST rate for the single-
lesion R-ZES subset was 0.3% and for the BMS group was 1.3% (adjusted hazard ratio
0.026, p=0.0125). The cumulative incidence of cardiac death or MI was similar for all
the groups (R-ZES 5.4%, EES 6.2%, R-ZES subset 4.3%, BMS 5.8%; p=ns for both).
Conclusion: Pooled data analysis confirms a low rate of ST and VLST up to 2 years
for R-ZES. Cardiac death or MI in patients treated with R-ZES through 2 years was
similar to EES. Further analysis of data with longer follow-up (2 yr follow up of R-
Int; 5 yr follow-up of R-FIM) will be presented.
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Background: Current guidelines recommend standard doses of aspirin and clopidogrel
following PCI. However, clinical studies show heterogeneity in responses to
antiplatelet therapy (APT) and high residual platelet reactivity is associated with
increased risk of adverse events, including stent thrombosis (ST). Individualized
assessment of response to APT has not been widely implemented largely due to lack
of a standardized and generally accepted platelet function test (PFT) appropriate for
routine clinical use. We investigated the prevalence of APT hyporesponsiveness in ST
and whether APT efficacy can be optimised with tailored therapy.
Methods: Between October 2009 and June 2011, 39 patients were admitted to our
institution with definite ST. Response to aspirin and clopidogrel was measured
following discharge using Short Thrombelastography (s-TEG), a simple, rapid and
reproducible PFT that has been developed and validated by this group. Changes to
APT were directed by s-TEG in hyporesponders and repeat testing undertaken
following treatment modification.
Results: Median time from index PCI to ST was 1125 days. At presentation, 2 (5%)
patients were on no APT (non-compliance), 11 (28%) were on both aspirin and
clopidogrel, 1 (3%) was on clopidogrel alone and 25 (64%) were on aspirin alone. s-
TEG testing showed that 12 (31%) patients had an adequate response to both aspirin
and clopidogrel, 16 (41%) were hyporesponsive to clopidogrel alone, 1 (3%) was
hyporesponsive to aspirin alone and 10 (26%) were hyporesponsive to both aspirin
and clopidogrel. Treatment modification in hyporesponders included an increase in
aspirin dose and/or changing clopidogrel to prasugrel. 3 patients who were
hyporesponsive to both clopidogrel and prasugrel were switched to ticagrelor. Out of
the 22 patients so far who have been retested following treatment modification, an
adequate response to APT has been achieved in 19 (86%). None have presented with
a further ST episode.
Conclusion: There is a high prevalence of hyporesponsiveness (69%) to aspirin and/or
clopidogrel in patients with ST. Improved APT efficacy can be achieved by tailored
therapy. s-TEG is a plausible PFT that can be used to deliver point-of-care personalized
APT. Further data are required to investigate the possibility of dynamic changes in
responses to APT and to determine whether tailored therapy leads to improved long
term clinical outcomes.
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Background: In light of the possible safety concerns from usage of drug-eluting stents
in complex populations, determining whether differences exist between on-label
(standard risk) or off-label (extended risk) use is important. Little is known in this
regard with second generation stents.
Methods: Using all available data, we analyzed 13,259 patients (7,841 on- and 5,418
off-label) receiving XIENCE V everolimus-eluting coronary stent systems (Abbott
Vascular, Santa Clara, CA) from 7 studies (3 pre-approval [SPIRIT II, III, IV] and 4
post-marketing [SPIRIT V and SPIRIT Women, XIENCE V USA, XIENCE V India]).
Definite/probable ST was adjudicated per Academic Research Consortium definition
by an independent clinical events committee.
Results: The 2-year cumulative ST rate in all patients receiving XIENCE V was 0.74%.
Dual antiplatelet therapy compliance and ST rates up to 730 days are shown in the
Table.
Conclusion: In this large, patient-level pooled safety analysis, the 2-year cumulative
ST rate in all patients receiving XIENCE V was 0.74% and was higher in the first year
with off-label use (0.39% on-label vs. 0.95% off-label). ST was uncommon after year
1 with everolimus-eluting stents (~0.1%) irrespective of on- or off-label usage.
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Background: Dual antiplatelet therapy (DAPT) interruption prior to 180 days (d) with
first generation DES is associated with a higher risk of stent thrombosis (ST). We
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